Search

Your search keyword '"Boers M"' showing total 1,655 results
Start Over Author "Boers M"
1,655 results on '"Boers M"'

52. Diagnostic criteria for early hip osteoarthritis: First steps, based on the CHECK study

Author

Runhaar, J., Ozbulut, O., Kloppenburg, M., Boers, M., Bijlsma, J.W.J., Bierma-Zeinstra, S.M.A., CREDO Expert Grp, Epidemiology and Data Science, AII - Inflammatory diseases, APH - Methodology, General Practice, Orthopedics and Sports Medicine, and Orthopaedic Biomechanics

Subjects
Male, musculoskeletal diseases, medicine.medical_specialty, WOMAC, Radiography, Physical examination, Osteoarthritis, Hip, Rheumatology, RC925, Hip osteoarthritis, Medicine, Humans, Pharmacology (medical), Medical history, Medical diagnosis, Range of Motion, Articular, Blood testing, AcademicSubjects/MED00360, medicine.diagnostic_test, business.industry, Clinical Science, Middle Aged, Reference Standards, hip osteoarthritis, diagnostic criteria, Physical therapy, Female, business, expert diagnosis, Cohort study, early diagnosis, Follow-Up Studies
Abstract

Objectives Although there is a general focus on early diagnosis and treatment of hip OA, there are no validated diagnostic criteria for early-stage hip OA. The current study aimed to take the first steps in developing diagnostic criteria for early-stage hip OA, using factors obtained through history taking, physical examination, radiography and blood testing at the first consultation in individuals presenting with hip pain, suspicious for hip OA, in primary care. Methods Data of the 543 individuals with 735 symptomatic hips at baseline who had any follow-up data available from the prospective CHECK cohort study were used. A group of 26 clinical experts [general practitioners (GPs), rheumatologists and orthopaedic surgeons] evaluated standardized clinical assessment forms of all subjects on the presence of clinically relevant hip OA 5–10 years after baseline. Using the expert-based diagnoses as reference standard, a backward selection method was used to create predictive models based on pre-defined baseline factors from history taking, physical examination, radiography and blood testing. Results Prevalence of clinically relevant hip OA during follow-up was 22%. Created models contained four to eight baseline factors (mainly WOMAC pain items, painful/restricted movements and radiographic features) and obtained area under the curve between 0.62 (0.002) and 0.71 (0.002). Conclusion Based on clinical and radiographic features of hip OA obtained at first consultation at a GP for pain/stiffness of the hip, the prediction of clinically relevant hip OA within 5–10 years was ‘poor’ to ‘fair’.

Published
2021
Full Text
View/download PDF

55. Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial.

Author

Ruwaard, J, L' Ami, MJ, Kneepkens, EL, Krieckaert, CLM, Nurmohamed, MT, Hooijberg, F, van Kuijk, AWR, van Denderen, JC, Burgemeister, L, Rispens, T, Boers, M, and Wolbink, GJ

Subjects
ANKYLOSING spondylitis, PSORIATIC arthritis, RHEUMATOID arthritis, RANDOMIZED controlled trials, ETANERCEPT
Abstract

The majority of patients with a rheumatic disease treated with etanercept may be overexposed. Data regarding etanercept tapering are scarce, particularly in psoriatic arthritis (PsA) and ankylosing spondylitis (AS). We compared extending the dose interval to continuation of the standard dose and studied the success rate of etanercept discontinuation. Etanercept concentrations were measured throughout the study. 160 patients with rheumatoid arthritis (RA), PsA, or AS with sustained minimal disease activity (MDA) were enrolled in this 18-month, open-label, randomized controlled trial. The intervention group doubled the dosing interval at baseline and discontinued etanercept 6 months later. The control group continued the standard dose for 6 months and doubled the dosing-interval thereafter. The primary outcome was the proportion of patients maintaining MDA at 6 month follow-up. At 6 months, MDA status was maintained in 47 patients (63%) in the intervention group and 56 (74%) in the control group (p = 0.15), with comparable results in all rheumatic diseases. And median etanercept concentrations decreased from 1.50 µg/mL (interquartile range 1.06– 2.65) to 0.46 µg/mL (0.28–0.92). In total, 40% discontinued etanercept successfully with maintained MDA for at least 6 months. Etanercept tapering can be done without losing efficacy in RA, PsA, and AS patients in sustained MDA. A substantial proportion of patients could stop etanercept for at least 6 months. In many patients, low drug concentrations proved sufficient to control disease activity. However, the risk of minor and major flares is substantial, even in patients continuing standard dosing. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

56. Diagnosis of early stage knee osteoarthritis based on early clinical course: data from the CHECK cohort

Author

Wang, Qiuke, Runhaar, Jos, Kloppenburg, Margreet, Boers, Maarten, Bijlsma, Johannes W. J., Bierma-Zeinstra, Sita M. A., Aerts-Lankhorst, N. E., Agricola, R., Bastick, A. N., van Bentveld, R. D. W., van den Berg, P. J., Bijsterbosch, J., de Boer, A., Boers, M., Bohnen, A. M., Boonen, A. E. R. C. H., Bos, P. K., Boymans, T. A. E. J., Breedveldt-Boer, H. P., Brouwer, R. W., Colaris, J. W., Damen, J., Elshout, G., Emans, P. J., Enthoven, W. T. M., Frölke, E. J. M., Glijsteen, R., van der Heide, H. J. C., Huisman, A. M., van Ingen, R. D., Jacobs, M. L., Janssen, R. P. A., Kevenaar, P. M., van Koningsbrugge, M. A., Krastman, P., Kuchuk, N. O., Landsmeer, M. L. A., Lems, W. F., van der Linden, H. M. J., van Linschoten, R., Mahler, E. A. M., van Meer, B. L., Meuffels, D. E., der Laan, W. H. Noort-van, van Ochten, J. M., van Oldenrijk, J., Pols, G. H. J., Piscaer, T. M., Vis, M., de Vries, A., Orthopaedic Biomechanics, Epidemiology and Data Science, AII - Inflammatory diseases, APH - Methodology, Rheumatology, AMS - Musculoskeletal Health, AMS - Tissue Function & Regeneration, Cardiology, ACS - Atherosclerosis & ischemic syndromes, ACS - Pulmonary hypertension & thrombosis, APH - Aging & Later Life, General Practice, and Orthopedics and Sports Medicine

Subjects
medicine.medical_specialty, Diseases of the musculoskeletal system, Osteoarthritis, Early clinical course, Cohort Studies, Internal medicine, medicine, Humans, Stage (cooking), Generalized estimating equation, CHECK cohort, Receiver operating characteristic, business.industry, Osteoarthritis, Knee, medicine.disease, Knee/diagnostic imaging, Rheumatology, Confidence interval, Osteoarthritis, Knee/diagnostic imaging, Early Diagnosis, RC925-935, ROC Curve, Cohort, Orthopedic surgery, Disease Progression, Knee osteoarthritis, business, Research Article
Abstract

Background Early diagnosis of knee osteoarthritis (OA) is important in managing this disease, but such an early diagnostic tool is still lacking in clinical practice. The purpose of this study was to develop diagnostic models for early stage knee OA based on the first 2-year clinical course after the patient’s initial presentation in primary care and to identify whether these course factors had additive discriminative value over baseline factors. Methods We extracted eligible patients’ clinical and radiographic data from the CHECK cohort and formed the first 2-year course factors according to the factors’ changes over the 2 years. Clinical expert consensus-based diagnosis, which was made via evaluating patients’ 5- to 10-year follow-up data, was used as the outcome factor. Four models were developed: model 1, included clinical course factors only; model 2, included clinical and radiographic course factors; model 3, clinical baseline factors + clinical course factors; and model 4, clinical and radiographic baseline factors + clinical and radiographic course factors. All the models were built by a generalized estimating equation with a backward selection method. Area under the receiver operating characteristic curve (AUC) and its 95% confidence interval (CI) were calculated for assessing model discrimination. Delong’s method compared AUCs. Results Seven hundred sixty-one patients with 1185 symptomatic knees were included in this study. Thirty-seven percent knees were diagnosed as OA at follow-up. Model 1 contained 6 clinical course factors; model 2: 6 clinical and 3 radiographic course factors; model 3: 6 baseline clinical factors combined with 5 clinical course factors; and model 4: 4 clinical and 1 radiographic baseline factors combined with 5 clinical and 3 radiographic course factors. Model discriminations are as follows: model 1, AUC 0.70 (95% CI 0.67–0.74); model 2, 0.74 (95% CI 0.71–0.77); model 3, 0.77 (95% CI 0.74–0.80); and model 4, 0.80 (95% CI 0.77–0.82). AUCs of model 3 and model 4 were slightly but significantly higher than corresponding baseline-factor models (model 3 0.77 vs 0.75, p = 0.031; model 4 0.80 vs 0.76, p = 0.003). Conclusions Four diagnostic models were developed with “fair” to “good” discriminations. First 2-year course factors had additive discriminative value over baseline factors.

Published
2021
Full Text
View/download PDF

57. Réponse échographique et clinique de l’atteinte des synovites chez les patients atteints de rhumatisme psoriasique traités par sécukinumab : résultats de l’étude ULTIMATE

Author

D’Agostino, M.A., primary, Conaghan, P., additional, Schett, G., additional, Mandl, P., additional, Naredo, E., additional, Van den Bosch, F., additional, Burgos-Vargas, R., additional, Duggan, A.M., additional, Goyanka, P., additional, Gaillez, C., additional, and Boers, M., additional

Published
2021
Full Text
View/download PDF

59. MACROPHAGE PET/CT IMAGING OF THE FEET CAN CONTRIBUTE TO EARLY PREDICTION OF THERAPY OUTCOME IN RHEUMATOID ARTHRITIS

Author

Verweij, N. J. F., Ter Wee, M., De Jongh, J., Zwezerijnen, G. C. J., Yaqub, M., Van Schaardenburg, D., Voskuyl, A., Lems, W., Lammertsma, A. A., Boers, M., Van der Laken, C. J., Radiology and nuclear medicine, Epidemiology and Data Science, Rheumatology, AII - Inflammatory diseases, Amsterdam Neuroscience - Brain Imaging, AMS - Musculoskeletal Health, AMS - Tissue Function & Regeneration, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, APH - Methodology, and APH - Societal Participation & Health

Published
2021
Full Text
View/download PDF

60. Room-temperature sealing of microcavities by cold metal welding

Author

Decharat, A., Junchun Yu, Boers, M., Stemme, G., and Niklaus, F.

Subjects
Microelectromechanical systems -- Design and construction, Semiconductor wafers -- Thermal properties, Semiconductor wafers -- Structure, Semiconductor wafers -- Electric properties, Welding -- Usage, Engineering and manufacturing industries, Science and technology
Published
2009

61. Disease activity in women with ankylosing spondylitis remains higher under Tumour Necrosis Factor inhibitor treatment than in men: a five-year observational study.

Author

Rusman, T, Nurmohamed, MT, Hoekstra, S, van Denderen, CJ, van Vollenhoven, RF, Boers, M, Ter Wee, MM, and van der Horst-Bruinsma, IE

Abstract

To assess sex differences in response, level of disease activity, and drug survival in tumour necrosis factor inhibitor (TNFi)-naïve ankylosing spondylitis (AS) patients. Consecutive AS patients, fulfilling the modified New York criteria, were included in a prospective cohort study at initiation of the first TNFi and followed until this medication was stopped (drug survival). Disease activity scores [AS Disease Activity Score using C-reactive protein (ASDAS-CRP), Bath AS Disease Activity Index (BASDAI), and CRP] were measured at 3, 6, and 12 months, and every subsequent year, up to 5 years. The response was defined by the ASDAS-CRP response criteria (clinically important improvement: ASDAS-CRP decrease ≥ 1.1). Analyses included regression methods for repeated measurements and survival analyses. Overall, 356 patients were included (34% women, mean ± sd age 46 ± 12 years), with a median disease duration of 12 (interquartile range 6;20) years. Women were less likely than men to achieve a clinically important response after 6 months of TNFi treatment (47% vs 64%; relative risk 1.4, 95% confidence interval (CI) 1.1;1.9, p = 0.02], despite a lack of sex differences in mean ASDAS-CRP levels over 5 year follow-up. Adjusted models for BASDAI over 5 years showed that women had a 0.6 point higher BASDAI score than men (β = 0.6 0.1;1.1 <0.02). Numerically, more women than men discontinued treatment over a period of 5 years (hazard ratio = 1.5, 95% CI 0.9;2.5, p = 0.15). Female AS patients show a lower response to TNFi and a higher disease activity compared to men. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

63. WHOLE BODY MACROPHAGE PET IMAGING THAT INCLUDES THE FEET CAN PROVIDE ADDITIONAL INFORMATION TO CLINICAL ASSESSMENT IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS

Author

Verweij, N. J. F., Ter Wee, M., De Jongh, J., Zwezerijnen, G. C. J., Yaqub, M., Boers, M., Voskuyl, A., Lammertsma, A. A., Lems, W., Van der Laken, C. J., Radiology and nuclear medicine, Epidemiology and Data Science, Rheumatology, AII - Inflammatory diseases, Amsterdam Movement Sciences, Amsterdam Movement Sciences - Rehabilitation & Development, Amsterdam Movement Sciences - Restoration and Development, AMS - Tissue Function & Regeneration, and APH - Methodology

Published
2020
Full Text
View/download PDF

64. Nationwide Outcomes of Advanced Melanoma According to BRAF(V600) Status

Author

Breeschoten, Jesper van, Wouters, Michel W.J.M., Wreede, L.C. de, Hilarius, Doranne H., Haanen, John B., Blank, Christian U., Blokx, Willeke A.M., Boers, M., Eertwegh, A.J. van den, Breeschoten, Jesper van, Wouters, Michel W.J.M., Wreede, L.C. de, Hilarius, Doranne H., Haanen, John B., Blank, Christian U., Blokx, Willeke A.M., Boers, M., and Eertwegh, A.J. van den

Abstract

Item does not contain fulltext

Published
2021

65. Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study

Author

Kooij, M.K. van der, Dekkers, Olaf M., Aarts, M.J., Berkmortel, Franchette W.P.J. van den, Boers, M., Groot, Jan Willem B. de, Eertwegh, A.J. van den, Kapiteijn, E., Kooij, M.K. van der, Dekkers, Olaf M., Aarts, M.J., Berkmortel, Franchette W.P.J. van den, Boers, M., Groot, Jan Willem B. de, Eertwegh, A.J. van den, and Kapiteijn, E.

Abstract

Contains fulltext : 238466.pdf (Publisher’s version ) (Open Access)

Published
2021

66. Towards developing diagnostic criteria for early knee osteoarthritis:Data from the CHECK study

Author

Runhaar, J., Kloppenburg, M., Boers, M., Bijlsma, J. W.J., Bierma-Zeinstra, S. M.A., Runhaar, J., Kloppenburg, M., Boers, M., Bijlsma, J. W.J., and Bierma-Zeinstra, S. M.A.

Abstract

Objectives: There is a general consensus that a shift in focus towards early diagnosis and treatment of knee OA is warranted. However, there are no validated and widely accepted diagnostic criteria for early knee OA available. The current study aimed to take the first steps towards developing diagnostic criteria for early knee OA. Methods: Data of 761 individuals with 1185 symptomatic knees at baseline were selected from the CHECK study. For CHECK, individuals with pain/stiffness of the knee, aged 45-65 years, who had no prior consultation or a first consultation with the general practitioner for these symptoms in the past 6 months were recruited and followed for 10 years. A group of 36 experts (17 general practitioners and 19 secondary care physicians) evaluated the medical records in pairs to diagnose the presence of clinically relevant knee OA 5-10 years after enrolment. A backward selection methods was used to create predictive models based on pre-defined baseline factors from history taking, physical examination, radiography and blood testing, using the experts' diagnoses as gold standard outcome. Results: Prevalence of clinically relevant knee OA during follow-up was 37%. Created models contained 7-11 baseline factors and obtained an area under the curve between 0.746 (0.002) and 0.764 (0.002). Conclusion: The obtained diagnostic models for early knee OA had 'fair' predictive ability in individuals presenting with knee pain in primary care. Further modelling and validation of the identified predictive factors is required to obtain clinically feasible and relevant diagnostic criteria for early knee OA.

Published
2021

70. OP0226 TOWARDS DEVELOPMENT OF AN ULTRASOUND ENTHESITIS SCORE IN PSORIATIC ARTHRITIS: 24-WEEK RESULTS FROM THE PHASE III RANDOMISED ULTIMATE STUDY

Author

D’agostino, M. A., primary, Conaghan, P. G., additional, Gaillez, C., additional, Boers, M., additional, Naredo, E., additional, Carron, P., additional, Hanova, P., additional, Cazenave, T., additional, Bakewell, C., additional, Duggan, A. M., additional, Goyanka, P., additional, and Schett, G., additional

Published
2021
Full Text
View/download PDF

71. AB0160 HIGH NUMBER OF CONCOMITANT MEDICATIONS AND COMORBIDITIES AT BASELINE IN THE GLUCOCORTICOID LOW-DOSE OUTCOME IN RHEUMATOID ARTHRITIS (GLORIA) STUDY: AN OLDER POPULATION WITH RHEUMATOID ARTHRITIS

Author

Boers, M., primary, Hartman, L., additional, Opris-Belinski, D., additional, Bos, R., additional, Kok, M. R., additional, Da Silva, J. A. P., additional, Griep, E. N., additional, Klaasen, R., additional, Allaart, C., additional, Baudoin, P., additional, Raterman, H., additional, Szekanecz, Z., additional, Buttgereit, F., additional, Masaryk, P., additional, Klausch, T., additional, Paolino, S., additional, Schilder, A., additional, Lems, W., additional, and Cutolo, M., additional

Published
2021
Full Text
View/download PDF

76. The Use of Placebo-Controlled and Non-inferiority Trials for the Evaluation of New Drugs in the Treatment of Postmenopausal Osteoporosis

Author

Delmas, P.D., Calvo, G., Boers, M., Abadie, E., Avouac, B., Kahan, A., Kaufman, J.M., Laslop, A., Lekkerkerker, J.F., Nilsson, P., Van Zwieten-Boot, B., Kreutz, G., and Reginster, J.Y.

Subjects
Postmenopausal women -- Research, Clinical trials -- Research, Osteoporosis -- Research, Osteoporosis -- Care and treatment, Health
Abstract

Byline: P. D. Delmas (1), G. Calvo (2), M. Boers (3), E. Abadie (4), B. Avouac (5), A. Kahan (6), J. M. Kaufman (7), A. Laslop (8), J. F. Lekkerkerker (9), P. Nilsson (10), B. Van Zwieten-Boot (11), G. Kreutz (12), J. Y. Reginster (13) Keywords: Key words:Clinical trial -- Drug registration -- Osteoporosis -- Placebo Abstract: Registration of new agents for the treatment of postmenopausal osteoporosis has been based over the past few years on placebo-controlled phase III trials with the incidence of patients with new vertebral/nonvertebral fractures as the most usual primary endpoint. The use of a placebo in diseases where an active treatment is available has been a matter of debate following the update of the Declaration of Helsinki by the World Medical Association which questioned this trial design. Current regulatory recommendations within the European Union suggest that placebo-controlled trials are still the best option when assessing the efficacy and safety of new drugs intended for the treatment of postmenopausal osteoporosis. This suggestion seems to be in apparent contradiction with the current content of the Declaration of Helsinki. This paper addresses the ethics and feasibility of placebo-controlled trials in the treatment of postmenopausal osteoporosis, in the light of available therapeutic options, and discusses possible alternative approaches in those patients where placebo treatment could be deemed to be unethical. It is concluded that placebo-controlled trials remain the most efficient design to establish the efficacy and safety of a new agent for the treatment of postmenopausal osteoporosis. Such trials are feasible and ethically acceptable in patients with osteoporosis but without prevalent vertebral fractures. Conversely, in patients with prevalent vertebral fractures, placebo-controlled trials are ethically questionable and non-inferiority trials are more appropriate. A relative margin of non-inferiority of 20--30% is suggested, to be discussed on a case by case basis. Author Affiliation: (1) INSERM Research Unit 403 and Claude Bernard University of Lyon, France, FR (2) Department of Clinical Pharmacology, Santa Creu i Sant Pau Hospital, Autonomous University of Barcelona, Spain, ES (3) Department of Clinical Epidemiology &amp Biostatistics, VU University Medical Center, Amsterdam, The Netherlands, NL (4) Agence Francaise du MeA'dicament, Saint-Denis, France, FR (5) Service de Rhumatologie, Ho^pital Henri Mondor, CreA'teil, France, FR (6) UniversiteA' de Paris V, AP-HP, Ho^pital Cochin, Paris, France, FR (7) Department of Endocrinology and Unit for Osteoporosis and Metabolic Bone Diseases, Ghent University Hospital, Belgium, BE (8) Department of Pharmacology, University of Innsbruck, Austria, AT (9) Medicines Evaluation Board, The Hague, The Netherlands, NL (10) Medical Product Agency, Uppsala, Sweden, SE (11) Medicines Evaluation Board, The Hague, The Netherlands, NL (12) BfArM ARM, Bonn, Germany , DE (13) Department of Epidemiology and Public Health, University of Lie`ge and World Health Organization Collaborating Center for Public Health Aspects of Rheumatic Disease, Lie`ge, Belgium, BE Article note: Received: 25 October 2001 / Accepted: 13 November 2001

Published
2002

78. Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count

Author

Hartman, Linda, primary, Cutolo, Maurizio, additional, Bos, Reinhard, additional, Opris-Belinski, Daniela, additional, Kok, Marc R, additional, Griep-Wentink, Hanneke (J) R M, additional, Klaasen, Ruth, additional, Allaart, Cornelia F, additional, Bruyn, George A W, additional, Raterman, Hennie G, additional, Voshaar, Marieke J H, additional, Gomes, Nuno, additional, Pinto, Rui M A, additional, Klausch, L Thomas, additional, Lems, Willem F, additional, and Boers, M, additional

Published
2021
Full Text
View/download PDF

79. Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*

Author

Thomas, K.S., primary, Apfelbacher, C.A., additional, Chalmers, J.R., additional, Simpson, E., additional, Spuls, P.I., additional, Gerbens, L.A.A., additional, Williams, H.C., additional, Schmitt, J., additional, Gabes, M., additional, Howells, L., additional, Stuart, B.L., additional, Grinich, E., additional, Pawlitschek, T., additional, Burton, T., additional, Howie, L., additional, Gadkari, A., additional, Eckert, L., additional, Ebata, T., additional, Boers, M., additional, Saeki, H., additional, Nakahara, T., additional, and Katoh, N., additional

Published
2021
Full Text
View/download PDF

83. Effet du sécukinumab sur la réduction des synovites évaluée par échographie Doppler puissance chez des patients atteints de rhumatisme psoriasique actif et naïfs de biothérapie : résultats d’une étude de phase 3 randomisée et contrôlée par placebo

Author

D’Agostino, M.A., primary, Schett, G., additional, Lopez Rodriguez, A., additional, Senolt, L., additional, Maldonado-Cocco, J., additional, Burgos-Vargas, R., additional, Naredo, E., additional, Carron, P., additional, Boers, M., additional, Duggan, A.M., additional, Goyanka, P., additional, and Gaillez, C., additional

Published
2020
Full Text
View/download PDF

84. Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting

Author

Thomas, K.S., primary, Apfelbacher, C.A., additional, Chalmers, J.R., additional, Simpson, E., additional, Spuls, P.I., additional, Gerbens, L.A.A., additional, Williams, H.C., additional, Schmitt, J., additional, Gabes, M., additional, Howells, L., additional, Stuart, B.L., additional, Grinich, E., additional, Pawlitschek, T., additional, Burton, T., additional, Howie, L., additional, Gadkari, A., additional, Eckert, L., additional, Ebata, T., additional, Boers, M., additional, Saeki, H., additional, Nakahara, T., additional, and Katoh, N., additional

Published
2020
Full Text
View/download PDF

88. AB1165 MEDICATION ADHERENCE DATA IN A RANDOMIZED TRIAL: LARGE CHALLENGES TO COME FROM RAW DATA TO A WORKABLE AND RELIABLE DATASET

Author

Hartman, L., primary, Alessandri, E., additional, Bos, R., additional, Opris-Belinski, D., additional, Kok, M. R., additional, Griep-Wentink, H., additional, Klaasen, R., additional, Allaart, C., additional, Bruyn, G., additional, Raterman, H., additional, Voshaar, M., additional, Gomes, N., additional, Pinto, R., additional, Klausch, T., additional, Lems, W., additional, and Boers, M., additional

Published
2020
Full Text
View/download PDF

89. FRI0581 IN ELDERLY PATIENTS, CAPS THAT RECORD MEDICATION BOTTLE OPENINGS ARE UNRELIABLE AND THUS NOT THE GOLD STANDARD FOR ADHERENCE

Author

Hartman, L., primary, Paolino, S., additional, Bos, R., additional, Opris-Belinski, D., additional, Kok, M. R., additional, Griep-Wentink, H., additional, Klaasen, R., additional, Allaart, C., additional, Bruyn, G., additional, Raterman, H., additional, Voshaar, M., additional, Gomes, N., additional, Pinto, R., additional, Klausch, T., additional, Lems, W., additional, and Boers, M., additional

Published
2020
Full Text
View/download PDF

90. OP0209 INTERVAL PROLONGATION IN ETANERCEPT-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITIS: AN OPEN-LABEL, RANDOMISED CONTROLLED TRIAL

Author

L’ami, M. J., primary, Ruwaard, J., additional, Kneepkens, E. L., additional, Krieckaert, C. L. M., additional, Nurmohamed, M., additional, Hooijberg, F., additional, Van Denderen, J. C., additional, Van Kuijk, A., additional, Burgemeister, L., additional, Boers, M., additional, and Wolbink, G. J., additional

Published
2020
Full Text
View/download PDF

92. THU0614-HPR ASSESSING THE EFFECT OF INTERVENTIONS FOR AXIAL SPONDYLOARTHRITIS ACCORDING TO THE ENDORSED ASAS/OMERACT CORE OUTCOME SET: A META-RESEARCH STUDY OF TRIALS INCLUDED IN COCHRANE REVIEWS

Author

Asmussen Andreasen, R., primary, Kristensen, L. E., additional, Baraliakos, X., additional, Strand, V., additional, Mease, P. J., additional, De Wit, M., additional, Ellingsen, T., additional, Jensen Hansen, I. M., additional, Kirkham, J., additional, Wells, G., additional, Tugwell, P., additional, Maxwell, L., additional, Boers, M., additional, Egstrup, K., additional, and Christensen, R., additional

Published
2020
Full Text
View/download PDF

99. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases

Author

van der Goes, M C, Jacobs, J W, Boers, M, Andrews, T, Blom-Bakkers, M A, Buttgereit, F, Caeyers, N, Choy, E H, Cutolo, M, Da Silva, J A, Guillevin, L, Holland, M, Kirwan, J R, Rovensky, J, Saag, K G, Severijns, G, Webber, S, Westhovens, R, and Bijlsma, J W

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results